ACADIA Pharmaceuticals Inc. (OQ:ACAD)

Business Focus: Biotechnology & Medical Research

Nov 10, 2020 09:00 am ET
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3:20 p.m. Eastern Time.
Nov 04, 2020 04:05 pm ET
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020.
Oct 26, 2020 09:00 am ET
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020.
Oct 21, 2020 04:05 pm ET
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Oct 14, 2020 04:05 pm ET
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
The Lewy Body Dementia Association (LBDA) and Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today an exclusive partnership on the production and release of a disease education adaptation of the new film Robin’s Wish©, a documentary detailing the late actor Robin Williams’ courageous battle with the neurodegenerative disorder, Lewy body dementia (LBD).
Oct 01, 2020 09:00 am ET
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of Directors. Dr. Garofalo is a biopharma executive with more than 25 years of experience in global clinical development and regulatory affairs.
Sep 02, 2020 09:00 am ET
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences:
Aug 31, 2020 09:00 am ET
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Gudarz Davar as Executive Vice President and Head of Research and Development. Dr. Davar will be responsible for leading research and development activities at ACADIA and will serve as a member of the company’s Executive Management Committee. In this role, he will report to Serge Stankovic, M.D., M.S.P.H., President of ACADIA. Dr. Stankovic will continue to oversee research and development, regulatory, medical affairs, external innovation and pharmacovigilance functions for the company.
Aug 25, 2020 09:00 am ET
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. The lead development program is a unique Reactive Species Decomposition Accelerant (RSDAx), a first-in-class mechanism focused on interrupting pathways that sensitize neurons to pain. The portfolio contains additional preclinical stage molecules, including brain penetrant molecules, with potential for symptomatic and
Aug 12, 2020 09:00 am ET
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m. Eastern Time.
Aug 05, 2020 04:05 pm ET
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2020.
Jul 30, 2020 03:37 pm ET
SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)
Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) for breach of fiduciary duties on the part of its directors and management.
Jul 29, 2020 09:00 am ET
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of dementia-related psychosis on more than 200 patients to better understand the patient-centered experience of symptoms and unmet treatment needs. Both patients and caregivers responded to the survey. These data were presented today in two posters during the
Jul 22, 2020 04:05 pm ET
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Wednesday, August 5, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Jul 20, 2020 04:03 pm ET
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Demen
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).
Jul 20, 2020 04:02 pm ET
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder (MDD). The combined efficacy and safety analysis was pre-specified prior to data unblinding following feedback from the FDA.
Jun 15, 2020 09:00 am ET
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA previously granted Breakthrough Therapy Designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP.
Jun 02, 2020 09:00 am ET
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020, at 4:40 p.m. Eastern Time.
May 28, 2020 09:00 am ET
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. Mr. Schneyer will be responsible for sourcing and executing business development opportunities and serve as a member of the company’s Executive Management Committee. He will report to Steve Davis, Chief Executive Officer.
May 26, 2020 09:00 am ET
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating pimavanserin for the adjunctive treatment of major depressive disorder (MDD) into one study with a pre-specified statistical analysis plan. As a result, no new patients will be enrolled in the two identically designed Phase 3 studies, each of which will be concluded with slightly more than 50% enrollment. Top-line results from the combined study are expected in the third quarter
May 21, 2020 09:00 am ET
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020 American Society of Clinical Psychopharmacology (ASCP) Virtual Annual Meeting on May 29-30, 2020.
May 07, 2020 04:06 pm ET
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the quarter ended March 31, 2020.
May 07, 2020 04:05 pm ET
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Vanderbilt University today announced an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of central nervous system (CNS) disorders. The collaboration will focus on positive allosteric modulators (PAMs) of the M1 receptor.
May 05, 2020 04:05 pm ET
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the following two investor conferences:
Apr 15, 2020 04:05 pm ET
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Mar 03, 2020 05:50 pm ET
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA review of a New Drug Application for another product in an expedited period of six months.
Feb 26, 2020 04:05 pm ET
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2019.
Feb 24, 2020 09:00 am ET
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, at 2:10 p.m. Eastern Time.
Feb 12, 2020 09:00 am ET
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on February 26, 2020, at 5:00 p.m. Eastern Time to discuss financial results and operations.
Jan 07, 2020 09:00 am ET
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020, at 10:00 a.m. Pacific Time, followed by a question and answer breakout session.
Dec 18, 2019 04:05 pm ET
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer. Ms. Fagan will be responsible for all corporate communications and serve as a member of the company’s Executive Management Committee. She will report to Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer of ACADIA.
Dec 04, 2019 08:45 pm ET
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today presented positive top-line results from its Phase 3 HARMONY study at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, December 4 -7, 2019 in San Diego, California. HARMONY was a double-blind, placebo-controlled, relapse prevention study in 392 patients evaluating pimavanserin for the treatment of dementia-related psychosis.
Nov 25, 2019 04:03 pm ET
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced positive top-line results from its ADVANCE study, a 26-week, randomized, double-blind, placebo-controlled study in 403 patients. ADVANCE evaluated the efficacy and safety of adjunctive pimavanserin treatment in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with their existing antipsychotic treatment. No drug is approved by the FDA for the treatment of the negative symptoms of schizophrenia.
Nov 11, 2019 09:00 am ET
ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a treatment for dementia-related psychosis at the upcoming 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting.
Nov 04, 2019 09:00 am ET
ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the appointment of Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer. Dr. Subbiah will report to Serge Stankovic, M.D., M.S.P.H., ACADIA’s President and be responsible for corporate medical affairs including medical strategy, scientific communications, and medical science liaison activities.
Oct 30, 2019 04:15 pm ET
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it has initiated the Phase 3 LAVENDER placebo-controlled study to evaluate the efficacy and safety of trofinetide for girls and young women with Rett syndrome. Rett syndrome is a serious and rare neurodevelopmental congenital CNS disorder with symptoms that typically present between six to 18 months of age, and lead to problems with cognitive, sensory, motor
Oct 30, 2019 04:05 pm ET
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2019.
Oct 16, 2019 09:00 am ET
ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the third quarter ended September 30, 2019 on Wednesday, October 30, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, October 30, 2019, at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and operations.
Oct 07, 2019 09:00 am ET
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that based on secondary analyses from its Phase 2 CLARITY study, adjunctive pimavanserin showed the potential to improve symptoms of sexual dysfunction experienced by patients with major depressive disorder (MDD). These additional data were presented in the poster, “Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder With Adjunctive Pimavanserin” at the 2019 Psych Congress, October 3-6 in San Diego, California.
Oct 03, 2019 04:55 pm ET
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Me
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral communication at the upcoming 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, December 4-7, 2019 in San Diego, California.
Sep 25, 2019 04:05 pm ET
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 3:00 p.m. Eastern Time in New York City.
Sep 24, 2019 04:05 pm ET
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), announced today that positive results from the Phase 2 CLARITY study evaluating pimavanserin as adjunctive treatment in patients with major depressive disorder (MDD) have been published online by The Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology (ASCP). In this 10-week, randomized, double-blind, placebo-controlled study (n=207), pimavanserin met the overall primary endpoint of the study by significantly reducing the 17-item Hamilton Depression Rating Scale (HAMD-17) total sco
Sep 23, 2019 09:00 am ET
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive results from an 8-week, open-label, single-arm Phase 2 study evaluating an investigational use and safety of pimavanserin as a monotherapy or adjunct to selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) therapy for Parkinson’s disease (PD) patients with depressive symptoms. These results were presented today during a poster session at the 2019 International Congress of Parkinson’s Disease and Movement Disorders® (MDS) in Nice, France.
Sep 20, 2019 04:05 pm ET
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, which includes 937,500 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $40.00 per share. The gross proceeds from the offering to ACADIA, before deducting
Sep 19, 2019 09:00 am ET
ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will present several scientific posters at the upcoming International Congress of Parkinson’s Disease and Movement Disorders® on September 22-26, 2019 in Nice, France and at the annual Psych Congress on October 3-6, 2019 in San Diego, California.
Sep 17, 2019 11:00 pm ET
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock, offered at a price to the public of $40.00 per share. The gross proceeds from this offering to ACADIA are expected to be approximately $250 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has gran
Sep 17, 2019 04:02 pm ET
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Sep 09, 2019 09:31 am ET
Thinking about buying stock in Acadia Pharmaceuticals, Aurora Cannabis, Bank of America, SINTX Technologies, or AT&T?
NEW YORK, Sept. 9, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, ACB, BAC, SINT, and T....
Sep 09, 2019 06:30 am ET
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its Phase 3 HARMONY study, a double-blind, placebo-controlled relapse prevention trial evaluating pimavanserin for the treatment of dementia-related psychosis, met its primary endpoint, demonstrating a highly statistically significant longer time to relapse of psychosis with pimavanserin compared to placebo in a planned interim efficacy analysis.
Sep 04, 2019 09:00 am ET
ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11, 2019 at 8:45 a.m. Eastern Time in New York City.
Jul 31, 2019 04:05 pm ET
ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2019.
Jul 22, 2019 04:05 pm ET
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy. A total of 396 patients with moderate-to-severe psychotic symptoms were randomized to receive either pimavanserin or placebo added to their current antipsychotic treatment. There is currently no FDA-approved adjunctive treatment for schizophrenia patients with inadequate response to existing therapies.
Jul 17, 2019 09:00 am ET
ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, July 31, 2019, at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and operations.
Jun 04, 2019 09:00 am ET
ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 1:20 p.m. Pacific Time in Rancho Palos Verdes, California.
May 18, 2019 11:00 am ET
ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder (MDD) at the 2019 American Psychiatric Association Annual Meeting in San Francisco, May 18 – 22, 2019.
May 07, 2019 09:00 am ET
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2019 on Tuesday, May 14, 2019 at 10:40 a.m. Pacific Time in Las Vegas.
May 01, 2019 04:05 pm ET
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the first quarter ended March 31, 2019.
Apr 25, 2019 09:00 am ET
ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in the upcoming months. These studies will evaluate the efficacy and safety of pimavanserin as adjunctive treatment in patients with major depressive disorder (MDD) who have an inadequate response to standard anti
Apr 17, 2019 09:00 am ET
ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the first quarter ended March 31, 2019 on Wednesday, May 1, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, May 1, 2019, at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and operations.
Apr 11, 2019 09:00 am ET
ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced support of several educational events for the Parkinson’s disease community and their ca
Apr 02, 2019 09:00 am ET
ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m. Eastern Time in New York City.
Apr 01, 2019 09:00 am ET
ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer. Ms. Ridloff joined ACADIA Pharmaceuticals in April 2018 as Senior Vice President, Investor Relations and has served as the company’s Interim Chief Financial Officer since October 2018.
Mar 29, 2019 07:20 am ET
Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics — Research Highlights Growth, Revenue, and Consolidated Resu
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of American Water Works Company, Inc. (NYSE:AWK), TripAdvisor, Inc....
Mar 27, 2019 04:10 pm ET
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Neuren Pharmaceuticals Limited (ASX: NEU), and Rettsyndrome.org (RSO) announced today that the positive results from a Phase 2 study conducted by Neuren, which evaluated the safety and efficacy of trofinetide in females with Rett syndrome (RTT), have been published in Neurology®, the medical journal of the American Academy of Neurology.
Mar 04, 2019 09:00 am ET
ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019, at 11:20 a.m. Eastern Time in New York City.
Feb 26, 2019 04:05 pm ET
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and full year ended December 31, 2018.
Feb 21, 2019 09:00 am ET
ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m. Eastern Standard Time in New York City.
Feb 13, 2019 08:15 am ET
New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives an
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of WPX Energy, Inc. (NYSE:WPX), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD),...
Feb 12, 2019 09:00 am ET
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2018 on Tuesday, February 26, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Tuesday, February 26, 2019, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial
Jan 11, 2019 06:08 pm ET
Glancy Prongay & Murray LLP Announces Investigation On Behalf Of ACADIA Pharmaceuticals Inc. Investors (ACAD)
Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (“ACADIA” or “the Company”) and whether the Company’s officers and directors complied with...
Dec 20, 2018 01:48 am ET
ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019, at 11:00 a.m. Pacific Standard Time, followed by a question and answer breakout session at 11:30 a.m.
Dec 03, 2018 08:10 am ET
Analysis: Positioning to Benefit within Symantec, ACADIA Pharmaceuticals, Novavax, BBX Capital, Paychex, and US Foods Holding — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Symantec Corporation (NASDAQ:SYMC), ACADIA Pharmaceuticals Inc....
Nov 30, 2018 04:05 pm ET
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 18,602,941 shares of its common stock, including 2,426,470 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $17.00 per share. The gross p
Nov 27, 2018 09:20 pm ET
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 16,176,471 shares of its common stock, offered at a price to the public of $17.00 per share. The gross proceeds from this offering to ACADIA are expected to be approximately $275.0 million, before deducting underwriting discounts and commissions and other estimated
Nov 26, 2018 04:08 pm ET
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $200,000,000 of its common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Nov 06, 2018 04:05 pm ET
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial results for the third quarter ended September 30, 2018.
Oct 31, 2018 09:31 am ET
Thinking about buying stock in ACADIA Pharmaceuticals, Aurora Cannabis Inc, Ford, Facebook or Fiat Chrysler Auto?
NEW YORK, Oct. 31, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, ACB, F, FB, and FCAU....
Oct 31, 2018 06:30 am ET
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD) study in major depressive disorder (MDD). In the study, 207 adult patients with a confirmed inadequate response to existing first-line SSRI or SNRI therapy for MDD received adjunctive treatment of either 34 mg pimavanserin or placebo in addition to pre-existing first-line therapy for five weeks (Stage 1). Those patients who did not show a
Oct 29, 2018 04:35 pm ET
ACADIA Pharmaceuticals Announces Executive Leadership Change
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S. Young, Executive Vice President and Chief Financial Officer, will be leaving the organization effective October 31, 2018 to join another healthcare company. Elena Ridloff, CFA, Senior Vice President, Investor Relations will serve as the Company’s Interim Chief Financial Officer.
Oct 24, 2018 08:50 am ET
Market Trends Toward New Normal in UROGEN PHARMA, Cimarex Energy, Boingo Wireless, TransCanada, EXTRACTION O&G, and ACADIA Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of UROGEN PHARMA (NASDAQ:URGN), Cimarex Energy Co (NYSE:XEC), Boingo...
Oct 23, 2018 09:00 am ET
ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the third quarter ended September 30, 2018 on Tuesday, November 6, 2018, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Tuesday, November 6, 2018, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and ope
Sep 26, 2018 09:00 am ET
ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced two executive appointments: Robert Kaper, M.D., has joined ACADIA as Senior Vice President, Global Head of Medical Affairs, and Eliseo Salinas, M.D., M.Sc., has joined the company as Senior Vice President, Chief Scientific Officer and Head of External Innovation. In these newly created roles, Dr. Kaper will report
Sep 25, 2018 09:00 am ET
ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 9:45 a.m. Eastern Time in New York City.
Sep 21, 2018 10:00 am ET
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against ACADIA Pharmaceuticals Inc. (ACAD) & Lead Plaintiff Deadline - September 17, 2018
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.  (“Acadia” or the “Company”) (NASDAQ: ACAD) and certain of its officers, on behalf of...
Sep 20, 2018 05:15 pm ET
FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that the FDA has completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of NUPLAZID (pimavanserin) for patients with Parkinson’s disease psychosis. NUPLAZID is the only medicine approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID was approved by the FDA based on a pivotal Phase 3 study that demonstrated clinically robust and highly statistically significant
Sep 17, 2018 10:00 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, FIZZ, RMTI, TTPH and FB
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 16, 2018 10:50 pm ET
ACADIA PHARMACEUTICALS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ACADIA Pharmac
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD). Investor losses must relate to purchases of the Company’s securities between April 29, 2016 and July 9, 2018. This action is pending in the United States District Court for the Southern District of California.
Sep 16, 2018 10:00 am ET
CLASS ACTION UPDATE -- DEADLINE MONDAY for ACAD and FIZZ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 14, 2018 10:50 pm ET
ACADIA PHARMA 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Clas
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD). Investor losses must relate to purchases of the Company’s securities between April 29, 2016 and July 9, 2018. This action is pending in the United States District Court for the Southern District of California.
Sep 14, 2018 07:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:  ACAD) and certain of its officers.  The class action, filed in United States District Court, Southern...
Sep 14, 2018 12:45 pm ET
SHAREHOLDER ALERT: PM QRTEA LOGM NLSN ACAD RMTI TTPH FB GDS SKX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 13, 2018 06:57 pm ET
Investors: The Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)
Law Offices of Howard G. Smith reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ:...
Sep 13, 2018 06:48 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National Beverage, ACADIA, and Vuzix and Encourages Investors to Contact the Firm
Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National Beverage Corporation, ACADIA Pharmaceuticals, Inc., and Vuzix Corporation.  Stockholders have until the deadlines...
Sep 13, 2018 04:28 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LCI, ACAD and FB
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 13, 2018 03:11 pm ET
KESSLER TOPAZ MELTZER & CHECK, LLP:  Final Deadline Reminder for ACADIA PHARMACEUTICALS INC. Investors – ACAD
Kessler Topaz Meltzer Check, LLP reminds ACADIA Pharmaceuticals Inc. (Nasdaq:  ACAD) (“ACADIA”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Southern District of California on...
Sep 13, 2018 12:39 pm ET
MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against ACADIA Pharmaceuticals Inc. (“ACADIA” or “the Company”) (NASDAQ:
Sep 12, 2018 07:21 pm ET
Investors: The Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. (ACAD)
Law Offices of Howard G. Smith reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) securities between April 29, 2016 and July 9, 2018, inclusiv
Sep 12, 2018 02:49 pm ET
CLASS ACTION UPDATE for ACAD and FB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 10, 2018 09:00 am ET
Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced today publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin for the treatment of psychosis in Alzheimer’s Disease Psychosis in The Journal of Prevention of Alzheimer’s Disease (JPAD). These results further demonstrate that pimavanserin may have the potential to treat dementia-related psychosis, a condition which can be present in neurodegenerative diseases such as Alzheimer’s disease,
Sep 09, 2018 11:30 am ET
SHAREHOLDER ALERT: PDD AMPE NVRO PZZA ZN SBGI ACAD FIZZ TTPH FB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 08, 2018 12:32 pm ET
INVESTOR ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (“ACADIA” or the “Company”) on behalf of purchasers of the Company’s securities between April 29, 2016 and July 9,...
Sep 07, 2018 07:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:  ACAD) and certain of its officers. The class action, filed in United States District Court, Southern...
Sep 07, 2018 02:37 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, ABBV and FB
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 07, 2018 12:00 pm ET
September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.
National securities litigation law firm Glancy Prongay Murray LLP (“GPM”) reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals...
Sep 06, 2018 12:05 pm ET
CLASS ACTION UPDATE for GLCNF GLNCY, ACAD and FPI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 05, 2018 12:37 pm ET
SHAREHOLDER ALERT: TSLA LOGM GLCNF ACAD MD FPI RMTI ABBV GDS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 04, 2018 05:08 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, RMTI, ORCL, AMPE and CBS
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 04, 2018 05:05 pm ET
Hagens Berman Reminds Investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) of the September 17, 2018 Securities Class Action Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP reminds investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) of the September 17, 2018 Lead Plaintiff deadline in the pending securities class action.  If you purchased or otherwise acquired ACADIA securities...
Sep 04, 2018 01:00 pm ET
CLASS ACTION UPDATE for FPI and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 04, 2018 09:00 am ET
ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018, at 10:35 a.m. Eastern Time in New York City.
Sep 02, 2018 10:00 am ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)
Glancy Prongay Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California on behalf of persons and entities that acquired ACADIA Pharmaceuticals Inc. (“ACADIA”...
Sep 02, 2018 12:00 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, ACAD, RMTI and ABBV
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 01, 2018 08:20 am ET
ACAD NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Important Sept. 17 Deadline - ACAD
NEW YORK, Sept. 1, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for ACADIA investors under the federal securities laws....
Aug 31, 2018 10:50 pm ET
ACADIA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Law
Kahn Swick Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against...
Aug 31, 2018 08:24 pm ET
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) securities between April 29, 2016 and July 9,...
Aug 31, 2018 05:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:  ACAD) and certain of its officers.   The class action, filed in United States District Court, Southern...
Aug 31, 2018 10:47 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MRCY, MD, FPI and ACAD
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 31, 2018 08:25 am ET
New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations fo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Argos Therapeutics, Inc. (OTC:ARGS), Triumph Group, Inc. (NYSE:TGI), Rigel...
Aug 30, 2018 07:10 pm ET
September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.
National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company) (NASDAQ:
Aug 30, 2018 05:06 pm ET
SHAREHOLDER ALERT: GLNCY GLCNF ACAD GDS NLSN LOGM PDD NVRO LCI CBS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 30, 2018 12:54 pm ET
SHAREHOLDER ALERT: MRCY MD FPI ACAD TTPH FB ZN SBGI ORCL TSLA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 29, 2018 05:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
NEW YORK, Aug. 29, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ:  ACAD) and certain of its officers.   The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities that purchased ACADIA securities between April 29, 2016, and July 9, 2018, inclusive (the "Class Period"). The claims asserted herein are alleged against Acadia and certain of the Company's officers (collectively, "Defendants"),...
Aug 29, 2018 05:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
NEW YORK, Aug. 29, 2018 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ:  ACAD) and certain of its officers.   The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities that purchased ACADIA securities between April 29, 2016, and July 9, 2018, inclusive (the "Class Period"). The claims asserted herein are alleged against Acadia and certain of the Company's officers (collectively, "Defendants"), and ar...
Aug 29, 2018 01:12 pm ET
CLASS ACTION UPDATE for ACAD and TTPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 28, 2018 07:45 pm ET
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) securities between April 29, 2016 and July 9, 2018, inclusive (the “Class Period”). ACADIA investors have until September
Aug 28, 2018 06:00 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Acadia Pharmaceuticals, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc. (“Acadia” or the “Company”) (NASDAQ:ACAD) of the September 17, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Aug 28, 2018 02:24 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FIZZ, ACAD and FB
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 26, 2018 10:00 am ET
SHAREHOLDER ALERT: MRCY GLNCY GLCNF MD COOL FPI FIZZ SBGL GOGO ACAD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 24, 2018 10:50 pm ET
ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD), if they purchased the Company’s securities between April 29, 2016 and July 9, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
Aug 24, 2018 05:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:  ACAD) and certain of its officers.   The class action, filed in United States District Court, Southern...
Aug 24, 2018 01:58 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Acadia Pharmaceuticals, Inc.
NEW YORK, Aug. 24, 2018 /PRNewswire/ -- WeissLaw LLP, a national class action, shareholder rights law firm with offices in New York, Los Angeles, and Atlanta, announces an investigation of Acadia Pharmaceuticals, Inc. (the "Company" or "ACAD") (NASDAQ: ACAD), its Board of Directors, and certain Company officers, for among other things, possible breaches of fiduciary duty and violations of Federal and State laws. ...
Aug 24, 2018 11:15 am ET
CLASS ACTION UPDATE for FPI, FIZZ and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 23, 2018 04:38 pm ET
Rosen Law Firm Reminds ACADIA Pharmaceuticals Inc. Investors of Deadline – ACAD
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive...
Aug 23, 2018 02:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, FPI, FIZZ, ACAD, TTPH and ABBV
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 22, 2018 01:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COOL, FIZZ, GOGO, ACAD and TSLA
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 21, 2018 03:59 pm ET
SHAREHOLDER ALERT: GLNCY GLCNF COOL FIZZ SBGL GOGO ACAD ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 21, 2018 01:43 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ACADIA, Rockwell Medical, and LogMeIn, and Encourages Investors to Contact the Firm
Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of ACADIA Pharmaceuticals Inc., Rockwell Medical, Inc., and LogMeIn, Inc.  Stockholders have until the deadlines listed below to...
Aug 20, 2018 02:45 pm ET
CLASS ACTION UPDATE for ACAD and FB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 20, 2018 02:43 pm ET
CLASS ACTION UPDATE for HAIR and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 19, 2018 11:00 am ET
SHAREHOLDER ALERT: FIZZ ACAD FB ABBV TTPH RMTI HMNY GDS NLSN ZN SBGI ORCL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 18, 2018 09:15 pm ET
Kaskela Law LLC Announces Shareholder Class Action Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm – ACAD
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (“ACADIA” or the “Company”) on behalf of purchasers of the Company’s securities between April 29, 2016 and July 9,...
Aug 18, 2018 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:  ACAD) and certain of its officers. The class action, filed in United States District Court, Southern...
Aug 17, 2018 10:50 pm ET
ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD
NEW ORLEANS, Aug. 17, 2018 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD), if they purchased the Company's securities between April 29, 2016 and July 9, 2018, inclusive (the "Class Period").  This action is pending in the United States District Court for the Southern District of California....
Aug 17, 2018 05:53 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In ACADIA Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, Aug. 17, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ACADIA Pharmaceuticals, Inc. ("ACADIA" or the "Company") (NASDAQ:ACAD) of the September 17, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ...
Aug 17, 2018 11:13 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, FB, HMNY, NLSN, ZN and SBGI
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 17, 2018 10:00 am ET
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against ACADIA Pharmaceuticals Inc. (ACAD) and Lead Plaintiff Deadline: September 17, 2018
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.  (“Acadia” or the “Company”) (NASDAQ: ACAD) and certain of its officers, on behalf of...
Aug 16, 2018 12:47 pm ET
CLASS ACTION UPDATE for MRCY and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 15, 2018 05:35 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, HAIR and ACAD
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 15, 2018 09:36 am ET
INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) (“ACADIA”) investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of ACADIA securities between April 29, 2016 and July 9, 2018, inclusive (the “Class Period”).
Aug 14, 2018 05:20 pm ET
ACAD NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. – ACAD
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive...
Aug 13, 2018 01:00 pm ET
CLASS ACTION UPDATE for FPI, FIZZ and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 13, 2018 12:08 pm ET
CLASS ACTION UPDATE for FPI, FIZZ and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 12, 2018 11:45 am ET
SHAREHOLDER ALERT: MRCY GLNCY GLCNF MD FPI FIZZ SBGL ACAD ABBV TTPH RMTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 11, 2018 08:00 am ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:  ACAD) and certain of its officers.   The class action, filed in United States District Court, Southern...
Aug 10, 2018 10:50 pm ET
ACADIA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Law
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD), if they purchased the Company’s securities between April 29, 2016 and July 9, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
Aug 10, 2018 12:30 pm ET
SHAREHOLDER ALERT: UNM SBGL PCG ACAD RMTI TTPH FB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 09, 2018 05:13 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GLNCY, GLCNF, ORA, FPI, ACAD and RMTI
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 08, 2018 05:41 pm ET
SHAREHOLDER ALERT: HAIR TAL UNM ORA NWL PCG FLKS ACAD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 08, 2018 04:06 pm ET
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Acadia Pharmaceuticals Inc. Investors
The law firm of Kessler Topaz Meltzer Check, LLP reminds ACADIA Pharmaceuticals Inc. (Nasdaq:  ACAD) (“ACADIA”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Southern District of...
Aug 08, 2018 04:05 pm ET
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2018.
Aug 07, 2018 01:21 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NWL, GOGO and ACAD
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 06, 2018 07:10 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc. (“Acadia” or the “Company”) (NASDAQ:ACAD) of the September 17, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Aug 06, 2018 05:16 pm ET
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America.
Aug 06, 2018 04:52 pm ET
CLASS ACTION UPDATE for MRCY, GLNCY, GLCNF, FIZZ and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 06, 2018 12:16 pm ET
SHAREHOLDER ALERT: MD ORA SBGL NWL PCG ACAD RMTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 06, 2018 09:31 am ET
Thinking about buying stock in ACADIA Pharmaceuticals, bluebird bio Inc., Facebook, Netflix or NVIDIA?
CHICAGO, Aug. 6, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, BLUE, FB, NFLX, and NVDA....
Aug 04, 2018 11:00 am ET
ACAD ALERT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline – ACAD
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) between April 29, 2016 and July 9, 2018, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ACADIA investors under the federal securities laws.
Aug 03, 2018 10:50 pm ET
ACADIA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), if they...
Aug 03, 2018 06:54 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against ACADIA Pharmaceuticals Inc. and Certain Officers – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:  ACAD) and certain of its officers.  The class action, filed in United States District Court, Southern...
Aug 03, 2018 04:32 pm ET
Hagens Berman Reminds Investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) of the September 17, 2018 Securities Class Action Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP reminds investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) of the September 17, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired ACADIA securities...
Aug 03, 2018 02:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SBGL, ACAD and HMNY
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 02, 2018 10:22 am ET
SHAREHOLDER ALERT: MD ANW QCOM FIZZ NWL GOGO ACAD FB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 01, 2018 05:46 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MabVax, Farmland, and ACADIA, and Encourages Investors to Contact the Firm
Bragar Eagel Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of MabVax Therapeutics Holdings, Inc., Farmland Partners Inc., and ACADIA Pharmaceuticals Inc.  Stockholders have until the...
Aug 01, 2018 11:00 am ET
SHAREHOLDER ALERT: MD ANW DB QCOM PCG ACAD RMTI FB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 01, 2018 10:29 am ET
Investor Alert: Kaplan Fox Announces Investigation Of ACADIA Pharmaceuticals
NEW YORK, Aug. 1, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (Nasdaq: ACAD).  Investors who purchased ACADIA securities between April 29, 2016 and July 9, 2018 (the "Class Period") may be affected.  A complaint has been filed in the United States District Court, Southern District of California against ACADIA and certain executives on behalf of investors that acquired ACADIA securities during the Class Period....
Jul 31, 2018 05:22 pm ET
CLASS ACTION UPDATE for QCOM, ACAD and TTPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 31, 2018 11:27 am ET
SHAREHOLDER ALERT: COOL UNM ORA FIZZ NWL PCG ACAD RMTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 31, 2018 10:15 am ET
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed against ACADIA Pharmaceuticals Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) (“ACADIA”) on behalf of purchasers of ACADIA securities between April 29, 2016 and July 9, 2018, inclusive (the “Class Period”).
Jul 30, 2018 09:00 am ET
ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the second quarter ended June 30, 2018 on Wednesday, August 8, 2018, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, August 8, 2018, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and operati
Jul 29, 2018 10:16 am ET
CLASS ACTION UPDATE for MRCY, MD and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 27, 2018 10:50 pm ET
ACADIA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Law
NEW ORLEANS, July 27, 2018 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD), if they purchased the Company's securities between April 29, 2016 and July 9, 2018, inclusive (the "Class Period").  This action is pending in the United States District Court for the Southern District of California....
Jul 27, 2018 06:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MRCY, QCOM and ACAD
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 27, 2018 05:54 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm
Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc. (“Acadia” or the “Company”) (NASDAQ:ACAD) of the September 17, 2018 deadline to seek the role of lead plaintiff in a federal securities...
Jul 27, 2018 11:12 am ET
SHAREHOLDER ALERT: MRCY COOL ANW QCOM FIZZ GOGO ACAD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 26, 2018 05:08 pm ET
CLASS ACTION UPDATE for FPI, FIZZ and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 26, 2018 04:23 pm ET
KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (“ACADIA” or the “Company”) on behalf of purchasers of the Company’s securities between April 29, 2016 and July 9, 2018, inclusive (the “Class Period”).
Jul 26, 2018 04:15 pm ET
RM LAW Announces Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.
BERWYN, Pa., July 26, 2018 /PRNewswire/ --  RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD) securities between July 17, 2014 and July 3, 2018, inclusive (the "Class Period")....
Jul 26, 2018 12:15 pm ET
SHAREHOLDER ALERT: ATEN UNM ANW DB GLCNF GLNCY FPI NWL PCG ACAD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 26, 2018 10:31 am ET
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against ACADIA Pharmaceuticals Inc. - ACAD
RADNOR, Pa., July 26, 2018 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) ("ACADIA") on behalf of purchasers of ACADIA securities between April 29, 2016 and July 9, 2018, inclusive (the "Class Period")....
Jul 26, 2018 07:35 am ET
Analysis: Positioning to Benefit within Citigroup, Cinedigm, FS Investment, ACADIA Pharmaceuticals, San Juan Basin Royalty Trust, and Fortress Transportation and Infrastructure Investors — Research Hi
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Citigroup Inc. (NYSE:C), Cinedigm Corp (NASDAQ:CIDM), FS Investment...
Jul 25, 2018 04:45 pm ET
CLASS ACTION UPDATE for FIZZ, ACAD and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 25, 2018 04:21 pm ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.
Federman & Sherwood announces that on July 19, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of California against Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is A
Jul 25, 2018 04:17 pm ET
KESSLER TOPAZ MELTZER & CHECK, LLP – Announces Investor Securities Fraud Class Action Lawsuit against ACADIA Pharmaceuticals Inc. - ACAD
The law firm of Kessler Topaz Meltzer Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Southern District of California against ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD)...
Jul 25, 2018 01:53 pm ET
INVESTOR ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) (“ACADIA” or the “Company”) on behalf of purchasers of the Company’s securities between April 29, 2016 and July 9,...
Jul 25, 2018 10:59 am ET
SHAREHOLDER ALERT: MRCY ATEN QCOM REVG SBGL GOGO ACAD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 24, 2018 07:00 pm ET
Safirstein Metcalf LLP Announces That Class Actions Have Been Filed Against ACADIA Pharmaceuticals, Inc. - ACAD
Safirstein Metcalf LLP announces that class actions have been filed in the United States District Court Southern District of California against ACADIA Pharmaceuticals, Inc. ("ACADIA" or the "Company") (Nasdaq: ACAD) on behalf of purchasers of...
Jul 24, 2018 01:21 pm ET
CLASS ACTION UPDATE for ATEN, REVG and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 24, 2018 12:12 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. – ACAD
Pomerantz LLP is investigating claims on behalf of investors of  Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:ACAD).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jul 24, 2018 11:00 am ET
Jul 24, 2018 11:00 am ET
SHAREHOLDER ALERT: ATEN ANW DB QCOM FPI FIZZ SBGL ACAD FLR REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.